prime medicine(PRME) - 2025 Q3 - Quarterly Results

Exhibit 99.1 Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates -- New preclinical data for PM577 in Wilson's Disease (WD) to be presented at AASLD; on-track to file IND and/or CTA in H1'26, with initial clinical data expected in 2027 -- -- Nominated PM647 as development candidate for Alpha-1 Antitrypsin Deficiency (AATD); on-track to file IND and/or CTA in mid- 2026, with initial clinical data expected in 2027 -- -- Strengthened leadership team with the appointment of ...